Clinical Trials
7 trialsNCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT07109323 2025-08-07
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Recruiting
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT00027820 2019-12-20
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01658904 2016-06-01
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01435720 2014-09-11
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Senesco Technologies, Inc.
Phase 1/2 Unknown